BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep 2015;5:11710. [PMID: 26130141 DOI: 10.1038/srep11710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
2 Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH, Cheng TL. Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Sci Rep 2016;6:39119. [PMID: 27991598 DOI: 10.1038/srep39119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. J Formos Med Assoc 2019;118:1014-23. [PMID: 30448077 DOI: 10.1016/j.jfma.2018.10.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hsiao JL, Ko WS, Shih CJ, Chiou YL. The Changed Proportion of CD45RA+/CD45RO+ T Cells in Chronic Hepatitis C Patients During Pegylated Interferon-α with Ribavirin Therapy. J Interferon Cytokine Res 2017;37:303-9. [PMID: 28414566 DOI: 10.1089/jir.2016.0113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
5 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol 2018;33:291-7. [PMID: 28548299 DOI: 10.1111/jgh.13834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
6 Liu CH, Sheng WH, Sun HY, Hsieh SM, Lo YC, Liu CJ, Su TH, Yang HC, Liu WC, Chen PJ, Chen DS, Hung CC, Kao JH. Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. Sci Rep 2015;5:17410. [PMID: 26616669 DOI: 10.1038/srep17410] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
7 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Sci Rep 2015;5:15255. [PMID: 26469083 DOI: 10.1038/srep15255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]